Interim Results
Avacta Group plc
Interim results for the 6 months ended 31 October 2006
Avacta Group plc ("Avacta" or the "Company") announces its first set of results
since the acquisition of Avacta Limited by Readybuy plc ("Readybuy") during
August 2006 and since the change of name of Readybuy to Avacta. Avacta provides
advanced biophysics technology and services to the biopharmaceutical,
pharmaceutical, defence, security, and clinical diagnostics sectors.
KEY POINTS
* Successful reversal of Avacta into Readybuy during August 2006, together
with a placing of new ordinary shares in the capital of the Company to
raise £638,000, net of expenses (the "Placing")
* Development of the two broad technology platforms to proof of concept stage
* Identification of several end user defined applications employing these two
technology platforms
* Laboratory bench prototype of one device successfully trialled at the MOD
* Three year Master Service Agreement signed with UCB Celltech for the
provision of a broad range of biopharma analytical services
* IP protection programme is being actively progressed
Alastair Smith, Chief Executive Officer, commented:
"I am delighted with the progress that Avacta has made during the period since
admission to AIM.
"Avacta's technology development programme continues apace and I am
particularly pleased with the involvement of end users, such as UCB Celltech,
who play a key role in driving the process.
"In addition, the strong growth of Avacta's analytical services business,
driven by the launch of new service products to solve critical problems faced
by biopharmaceutical developers, is key to the Group moving forward. I believe
we are becoming well recognised for our expertise in this area. "
30 January 2007
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive
Officer
Tim Sykes, Chief Financial Officer
Nexus Financial Limited Tel: 020 7451 7050
Nicholas Nelson/Kathy Boate Nicholas.nelson@nexusgroup.co.uk
WH Ireland Limited Tel: 0161 832 2174
David Youngman
CHAIRMAN'S AND CHIEF EXECUTIVE OFFICER'S REPORT
I am delighted to report our maiden interim results following the successful
reversal of Avacta Limited into Readybuy on 8 August 2006. These results cover
the 6 month period ended 31 October 2006. As the transaction has been accounted
for using reverse acquisition accounting, these results include six months of
trading for Avacta Limited and 12 weeks of trading for Readybuy since the date
of the reverse takeover.
In the admission document dated 13 July 2006 ("the Admission Document") we set
out the following key strategic objectives which would be funded from the
proceeds of the Placing:
* To further the development of the detection technology platforms to proof
of concept stage;
* To finance the protection of Avacta's intellectual property;
* To finance the development of Avacta's analytical services business by
funding marketing and promotional activity; and
* To demonstrate the advantages of Avacta's technology to support potential
additional fund raising in due course.
We are pleased to report good progress against all these objectives. The
Group's key achievements during the period from the reverse takeover to 31
October 2006 and in the period since include:
The continued development of the detection technology platforms to proof of
concept stage - Development continues to meet the planning milestones and we
have moved sufficiently far along the product development pipeline to have
identified six application opportunities for the two broad technology
platforms: Spectratech and Nanoscreen. Both platforms have now reached proof of
concept stage for several applications and one prototype device has
successfully undergone a testing phase with the MOD. As stated in the Admission
Document, the directors of Avacta anticipate that additional funding will be
required to complete the development of this and other prototype devices and
eventually bring them to market.
The protection and funding of Avacta's intellectual property - Solid progress
has been made in this highly technical area. One patent application has
progressed to PCT stage and is awaiting examination, a further two UK patent
applications have been filed. New IPR is continually being identified and we
are working closely with our patent attorneys to protect these innovations at
an early stage.
The development of Avacta's analytical services business by funding marketing
and promotional activity - A business development programme is underway and our
team has been successful in raising the profile of the services of Avacta
Analytical Limited ("Avacta Analytical"), a subsidiary company, which has been
reflected in the sales pipeline. The Group has enjoyed a long term relationship
with UCB Celltech which was further crystallised during December 2006 with the
announcement of a three year Master Service Agreement to provide a broad
spectrum of biophysical analytical services. The launch of new analytical
services products for the biopharmaceutical industry is a strong driver for the
pipeline and Avacta Analytical expects to launch further new service products
in the near future.
The demonstration of the advantages of Avacta's technology to support potential
additional fund raising - The development of laboratory prototypes is an
essential step in demonstrating the advantages of Avacta's technologies and
this process is continuing rapidly. The potential of Avacta's technology is
reflected in the formation of collaborative partnerships with end users such as
UCB Celltech.
Financial Overview
The Group has adopted the principles of reverse acquisition accounting. This
requires that the results be presented as if Avacta Limited had acquired
Readybuy and that the results of Readybuy be consolidated from the date of that
acquisition.
Accordingly, the results for the half year ended 31 October 2006, provide for
six months of trading for Avacta Limited and 12 weeks of trading for Readybuy
since the Company's ordinary shares were re-admitted to trading on AIM on 8
August 2006 ("Admission").
The operating loss before the costs of Admission and the Placing was £498,000
(6 months ended 31 October 2005 - loss £48,000). This reflects the investment
in the development of our broad detection platforms to proof of concept stage
and our further development of the specific devices, along with our investment
in marketing of our analytical services. The costs of the Admission were
£388,000 of which £239,000 was taken to the profit and loss account and £149,000
was taken to the share premium account.
At 31 October 2006 the Group had cash of £838,000 and was debt free.
Employees
The directors would like to thank all management and staff at Avacta for their
dedication and commitment without which, of course, the substantial progress
would not have been possible.
Outlook
World demand for molecular analysis and detection capabilities should continue
to rise, driven by acute problems faced by biological drug developers, the
threat of natural outbreaks such as pandemic flu, the continuing potential for
terrorist attacks using biological and chemical pathogens and the move towards
point of care medical testing. Consequently, the benefits of Avacta's
technologies and services, particularly for biopharmaceutical analysis, are
rapidly becoming recognised.
Through the identification of end user problems in these high value sectors and
the provision of technologies and services to solve them, Avacta has marked out
a clear path for continued development and growth in the coming year.
Gwyn Humphreys Alastair Smith
Chairman Chief Executive Officer
Avacta Group plc
Consolidated Profit and Loss Account
For the six month period ended 31 October 2006
Unaudited Unaudited Unaudited
6 months 6 months Year ended
ended ended
31 October 31 October 31 July 2006
2006 2005
Note £000 £000 £000
Turnover 41 31 241
Operating costs (778) (79) (459)
Operating loss before (498) (48) (218)
Admission costs
Admission costs 2 (239) - -
Operating loss (737) (48) (218)
Net interest receivable 9 1 8
Loss before taxation (728) (47) (210)
Taxation 5 - 5
Retained loss (723) (47) (205)
Earnings per share
Basic 3 (0.11p) (0.01p) (0.03p)
Basic before exceptional (0.07p) (0.01p) (0.03p)
items
The group's trading activities recommenced during August 2006, when Avacta
Limited reversed into Readybuy. The principles of reverse acquisition
accounting have been adopted in the preparation of this interim statement and
this requires that the results of Avacta Limited be presented with the results
of Readybuy included from the date of acquisition. The comparative figures are
the consolidated results of Avacta Limited. All of the above activities during
the 6 month periods ended 31 October 2006 and 31 October 2005 and the year
ended 31 July 2006 are classified as continuing.
The company's accounting reference date has been changed to 31 July and,
accordingly, the annual comparative figures presented are for the year ended 31
July 2006.
Avacta Group plc
Consolidated balance sheet
For the six month period ended 31 October 2006
Unaudited Unaudited Unaudited
31 October 31 October 31 July 2006
2006 2005
Note £000 £000 £000
Fixed assets
Goodwill 4 3,563 - -
Tangible fixed assets 51 3 37
3,614 3 37
Current assets
Debtors 38 75 50
Cash at bank 838 326 175
876 401 226
Creditors : Amounts
falling due within one (206) (87) (67)
year
Net current assets 670 314 159
4,284 317 196
Capital and reserves
Called up share capital 747 747 747
Share premium 2,368 2,368 2,368
Reverse acquisition 1,944 (2,780) (2,734)
reserve
Profit and loss account (525) (18) (185)
Equity shareholders' 4,284 317 196
funds
Avacta Group plc
Consolidated Cashflow Statement
For the six month period ended 31 October 2006
Unaudited Unaudited Unaudited
6 months ended 6 months ended Year ended
31 October 31 October 31 July 2006
2006 2005
£000 £000 £000
Operating loss (737) (48) (218)
Depreciation and 2 1 3
amortisation
(Increase) / decrease in 284 (74) -
working capital
Net cash outflow from operating (451) (121) (215)
activities
Net cash inflow from servicing of 9 1 8
finance
Net cash inflow from taxation 5 - 5
Net cash inflow from acquisitions 1,038 - -
Net cash outflow from capital (39) (2) (37)
expenditure
Net cash outflow before use
of liquid resources and 562 (122) (239)
financing
Issue of ordinary share capital 15 381 381
Net cash inflow / (outflow) from 15 381 381
financing
Increase / (decrease) in cash in 577 259 142
the period
Analysis of net cash
Cash at bank and in hand 838 326 175
Avacta Group plc
Interim accounts
For the six month period ended 31 October 2006
Notes
1. The unaudited results for the six month period ended 31 October 2006 have
been prepared using the principles of reverse acquisition accounting. These
principles require that the accounting reflects the substance of the
transaction rather than the legal form of the transaction. As such, the
reverse acquisition by Avacta Limited of Readybuy has been recognised
rather than the legal transaction that actually took place, being the
acquisition of Avacta Limited by Readybuy via a share for share exchange.
Further, the historic consolidated profit and loss account, consolidated
balance sheet and consolidated cash flow statement of Avacta Limited are
presented rather than those of Readybuy. The balance sheet reflects the
share capital and share premium of the legal parent, Readybuy, at 31
October 2006. In order to provide meaningful comparables for shareholders,
this share capital and share premium has also been recognised at 31 October
2005 and 31 July 2006. These unaudited results do not constitute statutory
accounts within the meaning of Section 240 of the Companies Act 1985.
2. Admission costs
Unaudited Unaudited Unaudited
6 months 6 months Year ended
ended ended
31 October 31 October 31 July 2006
2006 2005
£000 £000 £000
Charges relating to the 239 - -
Admission
3. The calculation of earnings per share for the period is based on the loss
after taxation divided by the weighted average number of ordinary shares in
issue. Because of the reverse acquisition, it is necessary to use the total
number of shares in issue at 31 October 2006 as the base for the earnings
per share calculation for each period in order to present a meaningful
comparison. Accordingly, the number of issued ordinary shares as at 31
October 2006, being 669,327,344, has been used as the number of shares in
issue throughout each period.
4. During the period, Readybuy legally acquired the entire issued ordinary
share capital of Avacta Limited. However, the Group has adopted the
principles of reverse acquisition accounting and has reflected the
substance of the transaction rather than the legal form. Hence, the Group
has accounted for the acquisition as though Avacta Limited had acquired
Readybuy. The assets and liabilities arising from the acquisition are as
follows :
Provisional
fair value
£000
Cash at bank and in hand 1,038
Net current assets 61
Net assets acquired 1,099
Purchase consideration, settled in 4,662
shares
Provisional goodwill 3,563
Cash inflow on acquisition 1,038